Skip Navigation

Eric Lee Nuermberger, M.D.

Eric Lee Nuermberger, M.D.

Headshot of Eric Lee Nuermberger
  • Professor of Medicine
Male

Expertise

Infectious Disease, Infectious Diseases, Tuberculosis ...read more

Research Interests

Drug development for tuberculosis and non-tuberculous mycobacterial infections, including Mycobacterium ulcerans disease (Buruli ulcer) ...read more

Request an Appointment

Insurance Information

Main Phone

410-955-1725

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-1725
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287 map

Johns Hopkins Bayview Medical Center

Appointment Phone: 410-550-0501
4940 Eastern Avenue
Baltimore, MD 21224 map

Background

Dr. Eric Nuermberger is a Professor of Medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include infectious diseases, including tuberculosis. 

Dr. Nuermberger received his undergraduate degree in psychology from Kenyon University. He earned his M.D. from Vanderbilt. He completed his residency and a fellowship in infectious diseases at Johns Hopkins Hospital. 

His research interests include the translational aspects of drug development for treatment of tuberculosis and non-tuberculous mycobacterial infections. He works with mice and other models to develop new, shorter and more effective drug regimens for these challenging infections.

Dr. Nuermberger is a member of several professional organizations, including the American Society for Microbiology, the Infectious Diseases Society of America, and the American Thoracic Society.

...read more

Titles

  • Professor of Medicine

Departments / Divisions

Education

Degrees

  • MD; Vanderbilt University School of Medicine (1996)

Residencies

  • Internal Medicine; Johns Hopkins University School of Medicine (1999)

Fellowships

  • Infectious Diseases; Johns Hopkins University School of Medicine (2000)
  • Infectious Diseases; Johns Hopkins University School of Medicine (2003)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (2002)

Research & Publications

Research Summary

Dr. Nuermberger’s primary research interest is the experimental chemotherapy of TB. The work uses validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new drugs and drug regimens. A major goal is to identify new agents that can be combined together in novel regimens or combined with existing drugs to shorten the duration of TB therapy.

A newer interest is to develop improved animal models of non-tuberculous mycobacterial infection to enable a similar approach to drug and regimen development for these difficult-to-treat infections.

Technology Expertise Keywords

Tuberculosis; Drug Development; Antibiotic Resistance; Pharmacodynamics; Infectious Disease; Infectious Diseases

Selected Publications

View all on PubMed

Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, Nuermberger E. Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541OC. Online ahead of print. PMID: 34939891

Rifat D, Chen L, Kreiswirth BN, Nuermberger EL. Genome-Wide Essentiality Analysis of Mycobacterium abscessus by Saturated Transposon Mutagenesis and Deep Sequencing. mBio. 2021 Jun 29;12(3):e0104921. doi: 10.1128/mBio.01049-21. Epub 2021 Jun 15. PMID: 34126767

Almeida DV, Converse PJ, Omansen TF, Tyagi S, Tasneen R, Kim J, Nuermberger EL. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrob Agents Chemother. 2020;64(6):e00259-20

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015; 60:270-7 

Rosenthal IM, Zhang M, Williams K, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model, PLoS Medicine, 2007;4:e344

Academic Affiliations & Courses

Graduate Program Affiliation

Activities & Honors

Memberships

  • American Society for Microbiology
  • American Thoracic Society
  • Infectious Diseases Society of America

Professional Activities

  • Member, Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) Study Section, NIH Center for Scientific Review, 2021
  • Member, TB Transformative Science Group, AIDS Clinical Trial Group (2011 - 2019), 2021
  • Member, Scientific Advisory Committee, TB Alliance, 2016
  • Member, Scientific Advisory Committee, Médecins Sans Frontières MDR-TB Clinical Trial Initiative, 2014
Is this you? Edit Profile
back to top button